Related by context. All words. (Click for frequent words.) 75 multicenter randomized 74 prospective randomized controlled 74 randomized multicenter 73 subgroup analyzes 73 multicentre randomized 73 prospective randomized 72 prospective multicenter 72 prospective randomized multicenter 72 randomized 71 randomized controlled 71 blinded randomized 71 randomized clinical 71 multicentre 70 placebo controlled clinical 70 BRIM2 70 phase IIIb 70 Randomized controlled 70 multicenter 70 active comparator 69 noninferiority 69 trials RCTs 69 placebo controlled studies 69 multicenter prospective 69 double blinded randomized 69 sirolimus eluting stents 68 prospective multicentre 68 double blinded placebo 68 multicenter Phase II 68 prospective randomized placebo 68 randomized controlled clinical 68 pharmacokinetic PK 68 multicenter randomized controlled 68 riociguat 68 Carotid Revascularization Endarterectomy vs. 68 multicenter randomized placebo controlled 68 placebo controlled trials 68 dose escalation Phase 68 Randomised 68 genotypic resistance 68 randomized blinded 67 dose escalation 67 nab paclitaxel 67 morphometric vertebral fractures 67 NATRECOR ® 67 VADT 67 Multicenter 67 placebo controlled 67 randomized Phase III 67 randomized Phase IIb 67 pegylated interferon alfa 2b 67 multicenter multinational 67 prospective nonrandomized 67 prospective multicenter randomized 67 Randomized 67 controlled multicenter 67 rFVIIa 67 TRITON TIMI 67 viral kinetic 67 RE LY ® 67 substudy 67 subanalysis 67 prespecified 66 RE LY 66 MADIT II 66 placebo controlled randomized 66 prospectively defined 66 randomized multicenter trial 66 Meta analyzes 66 multicenter trials 66 retrospective cohort 66 sirolimus eluting 66 STRIDE PD 66 randomized multicentre 66 chemoradiotherapy 66 PRECiSE 66 metastatic HRPC 66 multicentric 66 label multicenter 66 CYPHER Stent 66 AVERROES 66 CARE HF 66 clevidipine 65 ATACAND 65 ENDEAVOR IV 65 ischemic cardiomyopathy 65 PREVENT IV 65 prospectively stratified 65 MERLIN TIMI 65 paclitaxel eluting stents 65 randomized controlled trial 65 non inferiority 65 ACCORD Lipid 65 unblinded 65 randomized controlled clinical trials 65 randomized clinical trials 65 composite endpoint 65 β blockers 65 TAXUS VI 65 randomized trials 65 ALLHAT 65 Subgroup analyzes 65 placebo controlled Phase 65 phase Ib 65 Randomized Evaluation 65 everolimus eluting stents 65 fosbretabulin 65 galiximab 65 ExTRACT TIMI 65 paroxysmal AF 65 ONTARGET 65 multicenter randomized double 65 symptomatic paroxysmal AF 65 multicenter clinical 65 dose dose escalation 65 antiarrhythmic drug 65 Thrombolysis 65 HCV SPRINT 65 blind randomized 65 Phase IIIb 65 HCV RESPOND 2 65 randomized crossover 65 retrospective observational study 65 RCTs 65 APTIVUS r 65 blinded randomized controlled 65 IMPROVE HF 65 recurrent glioblastoma multiforme 65 sirolimus eluting stent 65 eptifibatide 65 pharmacokinetics PK 64 teriflunomide 64 noninferior 64 CIMZIA TM certolizumab pegol 64 FOLPI 64 Subgroup analysis 64 dose titration 64 meta regression 64 randomized controlled multicenter 64 pharmacodynamic PD 64 PFO migraine 64 GORE VIABAHN Endoprosthesis 64 antihypertensive therapy 64 label dose titration 64 thorough QT 64 phase IIb clinical 64 ascending dose 64 relapsed MM 64 TMC# C# 64 randomized controlled trials 64 ABSORB trial 64 Phase III randomized 64 Phase 2b study 64 NCT# ClinicalTrials.gov 64 confirmatory clinical 64 XIENCE V PROMUS Stent 64 ConclusionThis 64 multivessel disease 64 analgesic efficacy 64 TNF alpha inhibitor 64 dosage regimens 64 APPRAISE 64 AIR CF3 64 multicenter placebo controlled 64 antiplatelet drugs 64 post hoc 64 neoadjuvant 64 observational cohort 64 everolimus eluting stent 64 randomized controlled trials RCTs 64 thromboembolic events 64 prospective observational 64 BARI 2D 64 masked placebo controlled 64 PRIMO CABG 64 Primary endpoints 64 Phase #/#a 64 MEND CABG II 64 QTc prolongation 64 phase IIa 64 landmark ATHENA 64 NICE SUGAR 64 PRECISE 64 pharmacodynamic effects 64 rt PA 64 arteriography 64 ACUITY trial 64 blinded randomized placebo controlled 64 DAPT 64 Stenting Trial CREST 64 CAMMS# 64 REALITY Trial 64 lipid lowering therapy 63 recurrent GBM 63 ASTEROID 63 antiangiogenic therapy 63 prospectively randomized 63 Intervention Effectiveness 63 superficial bladder cancer 63 EVEREST II 63 elective PCI 63 BRIM3 63 phase IIa clinical 63 biliary tract cancer 63 achieved statistical significance 63 Prospective Randomized 63 CANCIDAS 63 randomized placebo controlled 63 bezafibrate 63 oral rivaroxaban 63 carotid endarterectomy CEA 63 randomized Phase 2b 63 multicentre randomized double 63 keloid scarring 63 blind placebo 63 placebo controlled Phase III 63 logistic regression models 63 viral kinetics 63 TAXUS V 63 prucalopride 63 Pharmacokinetic 63 carotid artery stenting CAS 63 fallopian tube cancers 63 Placebo controlled 63 nonoperative 63 Acute Ischemic Stroke 63 MAGE A3 ASCI 63 ROCKET AF 63 mycophenolate mofetil 63 multicenter Phase III 63 EURIDIS 63 ongoing Phase 1b 63 efficacy endpoint 63 concurrent chemoradiation 63 prospective multicenter study 63 evaluating tivozanib 63 valvulopathy 63 fondaparinux 63 Observational studies 63 anti arrhythmic drug 63 conventional angiography 63 beta blocker therapy 63 aspirin clopidogrel 63 L PPDS 63 label multicenter randomized 63 CTEPH 63 aldosterone antagonist 63 CINQUIL 63 pharmacodynamics PD 63 Phase IIB 63 SYNTAX trial 63 multicentre prospective 63 sotalol 63 MEND CABG 63 Doxil ® 63 tocilizumab 63 Phase III VISTA 63 angiographic outcomes 63 bosentan 63 EchoCRT 63 doxorubicin docetaxel 63 thromboprophylaxis 63 cilostazol 63 Edge STudy 63 prospective cohort 63 adalimumab 63 observational studies 63 generalizability 63 CYPHER R Sirolimus eluting 63 multicenter randomized clinical 63 TAXUS Stent 63 ACTEMRA TM 63 XIENCE V demonstrated 63 dose escalation phase 63 TAXUS ATLAS 63 cediranib 62 postoperative chemotherapy 62 oncologic outcomes 62 BoNTA 62 coronary revascularization 62 Angiographic 62 meta analyzes 62 Xelox 62 blind multicenter 62 zotarolimus eluting stent 62 AIR CF1 62 echocardiographic 62 ACTIVE W 62 oral anticoagulation 62 demonstrated clinically meaningful 62 lymphadenectomy 62 Initiated Phase 62 dose regimens 62 recurrent malignant glioma 62 NSABP B 62 myocardial revascularization 62 RSD# oral 62 BR.# 62 placebo controlled dose escalation 62 transurethral resection 62 sorafenib Nexavar ® 62 NATRECOR R 62 colorectal liver metastases 62 patients undergoing CABG 62 Traficet EN 62 resectable pancreatic cancer 62 CYPHER ® Stent 62 thrombus aspiration 62 DLTs 62 periprocedural MI 62 pegylated liposomal doxorubicin 62 Cypher Stent 62 antithrombotic therapy 62 platelet inhibitor 62 comparator arm 62 Long Lesion 62 unstable angina UA 62 prospective observational studies 62 zotarolimus 62 salmeterol fluticasone 62 nondiabetic patients 62 NEVO RES 62 treatment naive genotype 62 acute coronary syndromes ACS 62 definite stent thrombosis 62 carotid artery stenting 62 AIR CF2 62 TAXUS Liberte Stent 62 tapentadol ER 62 tolvaptan 62 #:# randomization 62 PRE SURGE 62 myocardial ischemia 62 infusional 62 TMC# r 62 RRMS patients 62 Val HeFT 62 surgical revascularization 62 ASCEND HF 62 PRIMO CABG2 62 elotuzumab 62 surrogate endpoint 62 OPCAB 62 SIMPADICO 62 CIMZIA ™ 62 patients undergoing percutaneous 62 TAXUS IV 62 ARB telmisartan 62 MGd 62 Nesiritide 62 sirolimus stent 62 PARTNER Trial 62 metastatic RCC 62 sunitinib malate 62 blind randomized controlled 62 rosuvastatin #mg 62 CA4P 62 SPIRIT III 62 placebo controlled multicenter 62 immunohistochemical 62 dose proportionality 62 PREZISTA r 62 nesiritide 62 ximelagatran 62 desvenlafaxine succinate 62 SORT OUT III 62 INCB# [003] 62 PICSO ® 62 multicenter study 62 APTIVUS 62 LEXIVA r 62 NEVO 62 tolerability pharmacokinetics 62 irbesartan 62 PROMUS Element Stent 62 aortic insufficiency 62 randomized discontinuation 62 liver resection 62 Zemplar Capsules 62 GEM OS1 62 phase IIb study 62 pomalidomide 62 chest radiographs 62 ADVANCE PD 62 VFEND 62 GEM OS2 62 duplex ultrasonography 62 dabigatran etexilate 62 lipid lowering drugs 62 Edwards SAPIEN valve 62 prognostic variables 62 Dose escalation 62 Taxus Stent 62 empiric 62 ECASS 61 AIM HIGH 61 carotid stenting 61 DMARD 61 antiepileptics 61 percutaneous intervention 61 NSTE ACS 61 pimecrolimus cream 61 pain palliation 61 O PPDS 61 pertuzumab 61 RAPAFLO R 61 Coronary Artery Bypass Graft 61 left ventricular dysfunction 61 secondary efficacy endpoints 61 Kaplan Meier analysis 61 Neovascular AMD 61 Phase Ib clinical 61 ZOLINZA 61 non valvular atrial 61 RECORD1 61 ENDEAVOR II 61 icatibant 61 adenoma recurrence 61 Non inferiority 61 venous thromboembolic disease 61 Clinical Antipsychotic Trials 61 controlled multicenter Phase 61 gadobutrol 61 SPIRIT FIRST 61 tecarfarin 61 TAXUS Express2 61 CYPHER R Stent 61 SCD HeFT 61 revascularizations 61 IMPACT DCM 61 HF ACTION 61 PROactive study 61 percutaneous vertebroplasty 61 label multicenter Phase 61 randomized #:# 61 Phase Ib II 61 conditional logistic regression 61 sequential dose escalation 61 Phase IIIb study 61 Poisson regression 61 PCI ExTRACT TIMI 61 Augment Injectable 61 TAXUS Express Stent 61 NEVO ™ 61 AVOREN 61 Acute Decompensated Heart Failure 61 divalproex sodium 61 infliximab 61 KRN# 61 tanespimycin 61 ADAGIO study 61 mg/m2 cohort 61 velafermin 61 ritonavir boosted 61 F FDG PET 61 Prospective Randomized Trial 61 RezularTM 61 Patency 61 enzastaurin 61 receptor tyrosine kinase inhibitor 61 ToGA 61 electrophysiologic 61 multicentre study 61 phase IIb 61 unfractionated heparin UFH 61 Zevalin consolidation 61 Teriflunomide 61 stable angina 61 thromboembolic 61 meta analysis 61 cortical stimulation 61 eculizumab therapy 61 TAXUS stent 61 prostate cancer PCa 61 NO# [002] 61 alpha blocker 61 LUX Lung 61 tacrolimus ointment 61 genomic biomarker 61 secondary efficacy endpoint 61 Multivariate logistic regression 61 Multicenter Automatic Defibrillator Implantation 61 carotid stenosis 61 CALGB 61 CALGB # [002] 61 metaanalysis 61 EDEMA3 trial 61 coronary stenosis 61 MIST II 61 certolizumab 61 darunavir ritonavir 61 Pegylated Liposomal Doxorubicin 61 GORE TAG Device 61 ablative therapy 61 eplerenone 61 Phase Ib study 61 preoperative chemotherapy 61 abciximab 61 SPARCL 61 oral diclofenac 61 TAXUS Liberte Long 61 stage IIIB 61 COPERNICUS 61 intermittent dosing 61 radiographic outcomes 61 Amrubicin 61 retrospective observational 61 HIV HCV coinfected 61 abacavir Ziagen 61 observational study 61 GSK# [001] 61 NSABP C 61 drug eluting stent implantation 61 statistically significant p = 61 periprocedural 61 bendamustine 61 pharmacokinetic characteristics 61 GOUT 61 KRAS mutations occur 61 pharmacodynamic parameters 61 antiplatelet agents 61 BETAS 61 relapsed myeloma 61 thromboembolism 61 Percutaneous Coronary Intervention 61 colorectal adenoma 61 6R BH4 61 posaconazole 61 GAMMAGARD 61 BRAF inhibitor 61 bolus dose 61 platinum refractory 61 EOquin TM 61 angioplasty stenting 61 vidofludimus 61 atherosclerotic renal artery stenosis 61 efficacy tolerability 61 residual confounding 61 sorafenib Nexavar 61 GnRH agonist 61 pharmacokinetic interactions 61 symptomatic VTE 61 IV NSCLC 61 nonresponders 61 Toxicities 61 PIX# [002] 61 cinacalcet 61 SPIRIT IV 61 clazosentan 61 ACTEMRA 61 5-FU/LV 61 Bivalirudin 61 ICD therapy 60 intensive lipid lowering 60 Intervention Effectiveness CATIE 60 pharmacodynamic 60 GISSI HF 60 HORIZONS AMI trial 60 Randomized Phase 60 melphalan prednisone 60 antithrombotics 60 intravesical 60 anti leukemic 60 AIR2 Trial 60 liver transplant recipients 60 telaprevir dosing 60 teriparatide 60 blind randomized placebo 60 ADMIRE HF 60 tirofiban 60 UKPDS 60 EDEMA3 60 TORISEL 60 idraparinux 60 randomisation 60 Dasatinib 60 Deforolimus 60 urate lowering 60 plasma pharmacokinetics 60 assessing T DM1 60 BCIRG 60 dose escalation clinical 60 Pivotal Trial 60 alvespimycin 60 NYHA functional class 60 blinded placebo controlled 60 polyarticular 60 RE LY trial 60 Genous stent 60 stent restenosis 60 cerebral vasospasm 60 intravenous dosing 60 virologic failure 60 Cardiotoxicity 60 Antihypertensive 60 eosinophilic asthma 60 antimicrobial prophylaxis 60 NovoTTF 60 selenium supplementation 60 MoxDuo TM IR 60 abatacept 60 ZACTIMA 60 XELOX 60 Vascugel ® 60 Adalimumab 60 TEAEs 60 crizotinib PF # 60 label dose escalation 60 mg/m2 dose 60 resectable 60 ziprasidone 60 Secondary efficacy endpoints 60 Secondary endpoints 60 GnRH agonists 60 multicenter phase 60 metformin monotherapy 60 randomized #:#:# 60 antitumor effect 60 venlafaxine XR 60 immunomodulatory therapy 60 antiangiogenic agent 60 HuMax EGFr 60 DMARD therapy 60 sunitinib 60 pharmacodynamic profiles 60 neoadjuvant treatment 60 pharmacodynamic profile 60 double blind placebo 60 TACE 60 heavily pretreated 60 intracranial stenosis 60 cerebral microbleeds 60 radical cystectomy 60 antiretroviral naïve 60 reinfarction 60 Phase 2a trial 60 lenalidomide dexamethasone 60 SABCS 60 maximally tolerated dose 60 prospective longitudinal 60 aldosterone antagonists 60 prospective observational cohort 60 liposomal amphotericin B 60 multicentre randomized controlled 60 caspofungin 60 cisplatin vinorelbine 60 Proellex TM 60 Abciximab 60 virological failure 60 TAVR 60 prespecified secondary 60 opioid naive 60 Ceplene/IL-2 60 Akt inhibitor 60 HYVET 60 non selective NSAIDs 60 FDG-PET/CT 60 Panzem R NCD 60 antiarrhythmic 60 ß blockers 60 Kaplan Meier curves 60 Pharmacokinetic parameters 60 EGS# 60 Baseline characteristics 60 pivotal bioequivalence 60 strontium ranelate 60 biologic therapy 60 NLX P# 60 pyridostigmine 60 subtrochanteric 60 rosuvastatin Crestor 60 postoperative AF 60 SYNTAX 60 dose escalation study 60 renal denervation 60 chemotherapy docetaxel 60 Tumor Response 60 dosing cohort 60 haematologic 60 randomized multicenter Phase III 60 virologic 60 Clinical Outcomes Utilizing Revascularization 60 FOLFIRI 60 paricalcitol 60 coronary intervention 60 nonpharmacologic 60 protease inhibitor PI 60 antibiotic prophylaxis 60 stenoses 60 pharmacokinetic parameters 60 ticagrelor 60 Tyrima 60 eprotirome 60 hepatectomy 60 pharmacodynamic endpoints 60 DU #b 60 Phase 1b 60 randomized double 60 IIIa inhibitor 60 bicifadine 60 epidemiologic studies 60 Ranolazine 60 visilizumab 60 abacavir lamivudine 60 OMS# 60 adecatumumab 60 clinically meaningful differences 60 VP# [004] 60 transabdominal 60 histologically confirmed 60 hindfoot 60 renal artery stenosis 60 ascending doses 60 NP2 Enkephalin 60 CIMZIA TM 60 nicardipine 60 factorial design 60 Trandolapril 60 NCCTG N# 60 binary restenosis 60 ritonavir boosted lopinavir 60 Stenting 60 canakinumab 60 lipid lowering agents 60 concomitant medications 60 Myocardial Infarction Study 60 tumor histology 60 Phase III multicenter 60 plain radiographs 60 mixed hyperlipidemia 60 Unstable Angina 60 univariate 60 intraobserver 60 arthrography 60 perioperative mortality 60 rosuvastatin 60 Rosuvastatin 60 histopathological 60 neratinib 60 preclinical efficacy 60 alicaforsen enema 60 intravenous bisphosphonates 60 androgen suppression 60 ganetespib 60 levosimendan 60 glycoprotein IIb IIIa inhibitor 60 mg kg dose 60 delafloxacin 60 tumor necrosis 60 MADIT 60 QTc 60 anti arrhythmic 60 STEP BD 60 ancrod 60 unfractionated heparin 60 adjuvant colon cancer 60 fluvastatin 60 ALA PDT 60 papillary renal cell carcinoma 60 pharmacodynamic properties 59 CLARITY study 59 unstable angina pectoris 59 postapproval 59 antihypertensive drugs 59 Phase 1a 59 chlorambucil 59 multivariate analyzes 59 intravenous cyclophosphamide 59 Phase 2b randomized 59 Phase IIIb clinical 59 LVSD 59 NMIBC 59 bovine thrombin 59 somatostatin analog 59 attain statistical significance 59 ruboxistaurin 59 VTE prophylaxis 59 posttreatment 59 sonographically guided 59 prostate cancer CaP 59 multivariate Cox 59 LV dysfunction 59 ReoPro 59 lacosamide 59 oxycodone CR 59 peginterferon alfa 2b 59 multicenter Phase 59 randomized controlled Phase 59 coronary artery stenosis 59 postintervention 59 sipuleucel T 59 Tolvaptan 59 randomized discontinuation trial 59 Phase Ib 59 FOLFOX4 59 PERSEUS 59 #mg QD [002] 59 methotrexate therapy 59 unmeasured confounders 59 Zilver PTX stent 59 Infarct 59 WallFlex Biliary RX 59 KRAS status 59 ascending dose study 59 iniparib BSI 59 efavirenz EFV 59 Raloxifene Evaluation MORE 59 EmbraceAC 59 postoperative mortality 59 perioperative complications 59 brivaracetam 59 nonischemic 59 Phase #b/#a 59 bi ventricular pacing 59 stent implantation 59 bifurcation lesions 59 APTIVUS ritonavir 59 pramlintide metreleptin combination 59 hemodynamically significant 59 CoreValve System 59 tipranavir ritonavir 59 renal tumors 59 Endarterectomy 59 cardiac perfusion 59 tipranavir r 59 decitabine 59 PFO closure 59 BENICAR HCT 59 TDF FTC 59 mild hepatic impairment 59 trastuzumab emtansine T DM1 59 adjuvant radiotherapy 59 serum phosphorous 59 mITT population 59 vitreous hemorrhage 59 Pharmacokinetic studies 59 ADHF 59 MVA MUC1 IL2 59 dosing regimens 59 transfemoral 59 CLL8 59 inotropic therapy 59 hip resurfacing arthroplasty 59 ILLUMINATE 59 BOLDER II 59 retrospective cohort study 59 IFN alfa 59 ularitide 59 bronchial thermoplasty 59 Stent Restenosis 59 intracoronary 59 docetaxel chemotherapy 59 Acute Myocardial Infarction 59 micafungin 59 acetabular fractures 59 NHANES III 59 longitudinal cohort study 59 dose cohort 59 Relapsed Multiple Myeloma 59 pentoxifylline 59 bowel resection 59 paclitaxel eluting stent 59 warfarin therapy 59 LPV r 59 RoACTEMRA 59 vertebral fracture 59 dose escalation trial 59 sustained virological response 59 dipyridamole plus 59 Phase 2a clinical 59 cilengitide 59 coadministration 59 CorVue ™ 59 bevacizumab Avastin ® 59 pericardial effusion 59 trabectedin 59 locoregional recurrence 59 mCRC patients 59 LAGB 59 CLORETAZINE TM VNP#M 59 tigecycline 59 IOP lowering 59 NIHSS score 59 CYPHER ® Sirolimus eluting 59 Randomized Double blind 59 EGFR TKI 59 Chronic Heart Failure 59 GFT# 59 Dabigatran 59 pharmacokinetic PK study 59 candesartan 59 acute decompensated heart 59 Cloretazine 59 vessel occlusion 59 LCP AtorFen 59 CR# vcMMAE 59 bortezomib Velcade 59 Phase III randomized controlled 59 pharmacokinetic pharmacodynamic 59 nephrectomy 59 iniparib 59 Vascular Wrap 59 octreotide LAR 59 carboplatin paclitaxel 59 BAY #-# 59 antihypertensive medications 59 postoperative complication 59 PNH patients 59 MACCE 59 carotid artery stent 59 Rheos System 59 carotid IMT 59 biologic DMARDs 59 COU AA 59 CUSTOM III 59 transthoracic 59 dose pharmacokinetic 59 XIENCE V stent 59 VAPRISOL 59 Lipid Lowering Treatment 59 ARIXTRA 59 Refractory Angina 59 CCR5 inhibitor 59 lamotrigine 59 calcaneal fractures 59 chemoradiation therapy 59 colposuspension 59 neoadjuvant therapy 59 nadolol 59 topical NSAIDs 59 eribulin mesylate 59 Drug Eluting Stents 59 transapical approach 59 Aflibercept 59 ORENCIA ® 59 angiographic 59 antihypertensive agents 59 oral antidiabetes drugs 59 T2 lesions 59 NPH insulin 59 clomipramine 59 inhaled budesonide 59 gemcitabine Gemzar 59 comorbid conditions 59 hemostatic efficacy 59 certolizumab pegol 59 MMP inhibitors 59 pazopanib 59 dyslipidaemia 59 Capesaris 59 antithrombotic 59 RLAI 59 valve implantation 59 thienopyridines 59 evaluable subjects 59 glycoprotein IIb IIIa inhibitors 59 forodesine 59 axitinib 59 antiangiogenic agents 59 adjuvant therapy 59 interferon gamma 1b 59 olmesartan 59 ENDEAVOR clinical 59 MEVACOR 59 carotid stents 59 LUMINATE 59 UA NSTEMI 59 transarterial 59 safety tolerability pharmacokinetic 59 Fondaparinux 59 Aplidin 59 AZX# 59 ENGAGE AF TIMI 59 CR nPR 59 dalteparin 59 nonfatal MI 59 functional mitral regurgitation 59 boosted protease inhibitor 59 dyssynchrony 59 INTELENCE 59 insulin detemir 59 arthroplasties 59 esophagogastric 59 invasive candidiasis 59 pairwise comparisons 59 factor Xa inhibitor 59 PD LID 59 CLBP 59 placebo controlled clinical trials 59 Insulin PH# 59 HRCT 59 medically inoperable 59 rebleeding 59 acyclovir Lauriad R 59 hyperinsulinemic euglycemic clamp 59 stent DES 59 oncological outcomes 59 EEG abnormalities 59 Outpatient Setting 59 SCIg